Market Cap 2.22B
Revenue (ttm) 0.00
Net Income (ttm) -177.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 777,500
Avg Vol 1,317,062
Day's Range N/A - N/A
Shares Out 79.14M
Stochastic %K 19%
Beta 0.51
Analysts Strong Sell
Price Target $50.88

Company Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 378 6240
Address:
150 N. Radnor Chester Rd., Suite F200, Radnor, United States
CyclePhase
CyclePhase Feb. 18 at 3:46 PM
$MLYS Minerales y Logística is a speculative materials exposure. Asset monetization is required for rerating. Volatility remains elevated.
0 · Reply
Jakeipedia
Jakeipedia Feb. 18 at 3:34 PM
$MLYS added!
0 · Reply
Jakeipedia
Jakeipedia Feb. 11 at 10:38 PM
$MLYS can we get top line OSA trial data tomorrow 🙏
0 · Reply
ChessGM
ChessGM Feb. 9 at 5:29 PM
$MLYS Very strong lately. BO in the cards? https://youtu.be/UGquZKb1y4w
0 · Reply
G101SPM
G101SPM Feb. 6 at 7:17 PM
#OPTIONACTION $MLYS Mar 25 puts (volume: 46.1K, open int: 23.1K, implied vol: ~110%, prev day implied vol: 70%). 22.9K traded in a single transaction. Co is expected to report earnings late February. $HIMS Weekly Feb06 20 puts (volume: 19.8K, open int: 13.9K, implied vol: ~108%, prev day implied vol: 70%). 1K traded in a single transaction. FDA Director Dr. Marty Makary says "FDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products. The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs." Co is confirmed to report earnings February 23 after the close.
0 · Reply
VolumeAlchemy
VolumeAlchemy Feb. 4 at 9:47 AM
$MLYS automotive software, connected vehicle trend
0 · Reply
Theflash88
Theflash88 Feb. 4 at 1:33 AM
$MLYS Green on a very red day..I’ll take it..
0 · Reply
garygb
garygb Jan. 11 at 9:47 PM
$MLYS High hopes here.
0 · Reply
cubie
cubie Jan. 8 at 1:49 PM
$MLYS interesting indeed🤔, catalyst soon?
1 · Reply
CrispDry
CrispDry Jan. 7 at 7:36 PM
$MLYS taking advantage of the flat trading and building a position
0 · Reply
Latest News on MLYS
Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026

Dec 28, 2025, 8:03 AM EST - 7 weeks ago

Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026


3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 5 months ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY SNDX TVTX


CyclePhase
CyclePhase Feb. 18 at 3:46 PM
$MLYS Minerales y Logística is a speculative materials exposure. Asset monetization is required for rerating. Volatility remains elevated.
0 · Reply
Jakeipedia
Jakeipedia Feb. 18 at 3:34 PM
$MLYS added!
0 · Reply
Jakeipedia
Jakeipedia Feb. 11 at 10:38 PM
$MLYS can we get top line OSA trial data tomorrow 🙏
0 · Reply
ChessGM
ChessGM Feb. 9 at 5:29 PM
$MLYS Very strong lately. BO in the cards? https://youtu.be/UGquZKb1y4w
0 · Reply
G101SPM
G101SPM Feb. 6 at 7:17 PM
#OPTIONACTION $MLYS Mar 25 puts (volume: 46.1K, open int: 23.1K, implied vol: ~110%, prev day implied vol: 70%). 22.9K traded in a single transaction. Co is expected to report earnings late February. $HIMS Weekly Feb06 20 puts (volume: 19.8K, open int: 13.9K, implied vol: ~108%, prev day implied vol: 70%). 1K traded in a single transaction. FDA Director Dr. Marty Makary says "FDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products. The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs." Co is confirmed to report earnings February 23 after the close.
0 · Reply
VolumeAlchemy
VolumeAlchemy Feb. 4 at 9:47 AM
$MLYS automotive software, connected vehicle trend
0 · Reply
Theflash88
Theflash88 Feb. 4 at 1:33 AM
$MLYS Green on a very red day..I’ll take it..
0 · Reply
garygb
garygb Jan. 11 at 9:47 PM
$MLYS High hopes here.
0 · Reply
cubie
cubie Jan. 8 at 1:49 PM
$MLYS interesting indeed🤔, catalyst soon?
1 · Reply
CrispDry
CrispDry Jan. 7 at 7:36 PM
$MLYS taking advantage of the flat trading and building a position
0 · Reply
Jakeipedia
Jakeipedia Jan. 6 at 3:23 PM
$MLYS very excited for this stock and 2026. Let’s go
0 · Reply
OptionRunners
OptionRunners Dec. 29 at 2:37 PM
$MLYS those were closed out on Friday. OI dropped in all 3 strikes. Still a lot sitting in them though.
0 · Reply
OptionRunners
OptionRunners Dec. 26 at 7:55 PM
$MLYS seems like some of these may have gotten closed out this morning. 5,083 of the 40/30/60 spreads for $3.25. But need to see the OI to confirm.
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 6:09 PM
Biotech momentum is BACK — and these names are already up big 👀🚀 $MLYS, $LYEL, $NKTR and $INSM are all up more than 50% in 2025, powered by clinical wins, FDA approvals, and M&A deals that are reviving confidence across the drug and biotech space heading into 2026. See why these high-flyers may still have room to grow 👉 https://www.zacks.com/stock/news/2808693/4-drug-biotech-stocks-rising-more-than-50-in-2025-with-room-to-grow?cid=sm-stocktwits-2-2808693-teaser-26257&ADID=SYND_STOCKTWITS_TWEET_2_2808693_TEASER_26257
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 5:09 PM
$MLYS skyrocketed 203.4% YTD — is there more fuel in the tank? 🚀 Lorundrostat hit primary endpoints in key studies and an NDA is set for early 2026. With a Zacks Rank #2 (Buy), the setup looks promising for a continued run. Explore the full potential here 👉 https://www.zacks.com/stock/news/2808693/4-drug-biotech-stocks-rising-more-than-50-in-2025-with-room-to-grow?cid=sm-stocktwits-2-2808693-body-26256&ADID=SYND_STOCKTWITS_TWEET_2_2808693_BODY_26256
0 · Reply
Quantumup
Quantumup Dec. 19 at 4:09 PM
BofA⬆️ $MLYS's PT to $46 from $43/reiterated at Buy. $AZN $ALNY - $RHHBY $NVS Stifel⬆️PT to $52 from $45 and reiterated at Buy. Here's what Stifel had to say in its note: https://x.com/Quantumup1/status/2002047867654136129?s=20
0 · Reply
IN0V8
IN0V8 Dec. 19 at 3:41 PM
$MLYS Buy BofA Global Research raises PT to $46 from $43 Stifel raises target price to $52 from $45
0 · Reply
JarvisFlow
JarvisFlow Dec. 19 at 2:45 PM
Stifel has updated their rating for Mineralys Therapeutics ( $MLYS ) to Buy with a price target of 52.
0 · Reply
YEHMINGZHU
YEHMINGZHU Dec. 13 at 7:20 PM
$MLYS Lorundorestat is a highly selective Aldosterone Synthase Inhibitor (ASI). It works by targeting the over-production of aldosterone, a hormone that drives high blood pressure in many patients resistant to standard therapies. This trial's results were so impactful they were recognized in the Journal of the American Medical Association (JAMA) "Research of the Year" Roundup. I will be looking for an entry here as I believe it is de risked now. Data anticipated Q1 2026 and this drug is the only one being studied to address OSA. This is there opportunity to turn into a platform therapy. Can break above $50 or $60 on this readout. **No position yet**
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 11 at 1:12 AM
$MLYS Current Stock Price: $36.17 Contracts to trade: $35 MLYS Dec 19 2025 Call Entry: $0.40 Exit: $0.79 ROI: 99% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OptionRunners
OptionRunners Dec. 10 at 9:23 PM
$MLYS these got added again into the close. Total of 14,567 contracts today.
0 · Reply
OptionRunners
OptionRunners Dec. 10 at 7:37 PM
$MLYS again .. 35/30/60 this time
0 · Reply